Latest Insider Transactions at Verona Pharma PLC (VRNA)
This section provides a real-time view of insider transactions for Verona Pharma PLC (VRNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verona Pharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verona Pharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 04
2021
|
Mahendra Shah Director |
SELL
Open market or private sale
|
Direct |
10,680
-12.75%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
Martin Edwards Director |
SELL
Open market or private sale
|
Direct |
12,024
-9.77%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
David R Ebsworth Director |
SELL
Open market or private sale
|
Direct |
11,184
-1.61%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
10,016
-11.86%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
Kenneth Cunningham Director |
SELL
Open market or private sale
|
Direct |
13,112
-16.45%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
Lisa Deschamps Director |
SELL
Open market or private sale
|
Direct |
10,680
-9.21%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
Anders Ullman Director |
SELL
Open market or private sale
|
Direct |
12,056
-3.48%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
52,056
-0.29%
|
$0
$0.81 P/Share
|
|
May 03
2021
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,416
-0.06%
|
$0
$0.87 P/Share
|
|
May 03
2021
|
Mark W Hahn Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,122,448
-11.14%
|
$0
$0.89 P/Share
|
|
May 03
2021
|
David Zaccardelli President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,139,632
-10.67%
|
$0
$0.89 P/Share
|
|
Mar 01
2021
|
Lisa Deschamps Director |
BUY
Grant, award, or other acquisition
|
Direct |
116,000
+50.0%
|
-
|
|
Mar 01
2021
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
43,392
-0.22%
|
$43,392
$1.14 P/Share
|
|
Mar 01
2021
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
26,728
-0.14%
|
$26,728
$1.14 P/Share
|
|
Feb 01
2021
|
Kenneth Cunningham Director |
SELL
Open market or private sale
|
Direct |
13,104
-14.12%
|
$0
$0.99 P/Share
|
|
Feb 01
2021
|
David R Ebsworth Director |
SELL
Open market or private sale
|
Direct |
11,912
-1.68%
|
$0
$0.99 P/Share
|
|
Feb 01
2021
|
Martin Edwards Director |
SELL
Open market or private sale
|
Direct |
13,688
-10.01%
|
$0
$0.99 P/Share
|
|
Feb 01
2021
|
Mahendra Shah Director |
SELL
Open market or private sale
|
Direct |
10,800
-11.42%
|
$0
$0.99 P/Share
|
|
Feb 01
2021
|
Vikas Sinha Director |
SELL
Open market or private sale
|
Direct |
10,224
-10.8%
|
$0
$0.99 P/Share
|
|
Feb 01
2021
|
Anders Ullman Director |
SELL
Open market or private sale
|
Direct |
10,800
-3.02%
|
$0
$0.99 P/Share
|
|
Jan 28
2021
|
Mark W Hahn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,824
+0.55%
|
-
|
|
Jan 28
2021
|
David Zaccardelli President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
529,104
+2.57%
|
-
|